pp-017 Injection, pre-filled pen
Dossier type
CTD
Dossier status
Under development
Country of origin
China
Comments
Long-acting insulin analogue injection in Phase 3 for type 2 diabetes mellitus. Monotherapy aimed at improving basal glycemic control with sustained activity. Same class as degludec, glargine, and detemir.
Manufacturer #17216
Global developer of innovative drugs in oncology, metabolic, autoimmune, and cardiovascular diseases, with 14 in-house products and multiple partnerships. Over 5,000 R&D staff across global centers and strong IP, clinical pipeline, and high-standard manufacturing.
Manufacturer usually replies in 41 days